

## Ashwagandha as a potential Anti-Alzheimer's Drug

Abhishek Kumar<sup>1</sup>, Pankaj Kumar<sup>1</sup>, Prashant Nayak<sup>2</sup>, S. Pramatha<sup>1</sup>, Rupal Ria DSouza<sup>1</sup>, Sameeksha Suvarna<sup>1</sup>, Sanil Rohan Kumar<sup>1</sup>

Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS) <sup>1</sup>Department of Pharmaceutical Chemistry, Mangalore, India.

Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS) <sup>2</sup>Department of Pharmaceutics, Mangalore, India.

### ABSTRACT

Alzheimer's Disease (AD), also called as just Alzheimer's is a progressive neurodegenerative disease that is characterized by memory loss, disorientation, mood disorders, and behavioural changes. It commonly occurs in people above the age of 65, but early cases can start as early as mid-30s. The current medications for Alzheimer's are only palliative and include reversible cholinesterase inhibitors and Memantine, an NMDA antagonist. Various other drugs are also used to treat the behavioural and psychiatric changes that occur in the later stages of the disease. Root extracts of *Withania somnifera*, commonly called as Ashwagandha, have been shown to have anti-Alzheimer's activity, in silico, in-vitro and in-vivo. This activity of Ashwagandha is attributed mainly to 2 constituents; Withanosides and Withanolides. They are known to promote neurite outgrowth, reduce A $\beta$  toxicity, improve cognitive functions and also reduce cholinergic activity in the CNS, by inhibiting the enzyme acetyl cholinesterase.

KEYWORDS: Alzheimer's, Ashwagandha, *Withania somnifera*, Withanoside, Withanolide

### Corresponding author

Pankaj Kumar

E-mail: [pankajpgr@nitte.edu.in](mailto:pankajpgr@nitte.edu.in)

### INTRODUCTION

Alzheimer's disease was first described in 1906 by Alois Alzheimer, after whom the disease is named[1]. It is a neurodegenerative disease that primarily affects the hippocampus, the part of the brain associated with memory, which causes the classical symptom of Alzheimer's, which is memory impairment. The disease is idiopathic, i.e the cause is not definitively known, though risk factors have been identified. The disease is characterized by deposition of proteins in the brain, particularly two proteins called A $\beta$  (Amyloid- $\beta$ )[2] and tau protein[3]. The A $\beta$  protein causes amyloid plaques and the tau protein causes neurofibrillary tangles. It is also seen as a loss of neurons and synapses in certain regions of the brain like the cerebral cortex and some subcortical regions [4-5],

leading to degeneration of the temporal and parietal lobes, as well as the frontal cortex. Chemically, Alzheimer's is a proteopathy, an irregularity in protein generation and folding, which causes the deposition of  $A\beta$  as amyloid plaques and tau protein as neurofibrillary tangles. The diagnostic tests for Alzheimer's are through cognitive tests to assess cognitive function and CT scans (Computed Topography) or MRI (Magnetic Resonance Imaging) or PET (Positron Emission Topography) with certain radio opaque dyes like florbetapir and flutemetamol can help in identifying the affected areas, and the extent of disease progression[6]. There are several risk factors indicated in Alzheimer's, some of which are various forms of head injury, but the main risk factor is genetic[7]. Genetic causes account for less than 3% of the total Alzheimer's cases. This is called as early onset familial Alzheimer's[8]. Here, the disease is caused due to mutations in one of three genes that encode  $A\beta$ ; APP (Amyloid-Beta precursor protein), and two presenilins PSEN 1 and 2 [9]. Mutations in these genes causes excess production of the  $A\beta$  protein that gets deposited as amyloid plaques. In the case of non-familial Alzheimer's, many genes have been indicated as risk factors that increase the chances of Alzheimer's, such as the APOE (Apolipoprotein E) alleles and the alleles of the TREM 2 gene[10-11], but they are unconfirmed, due to variations between different populations. Though there are many hypotheses about the cause and progression of Alzheimers, the exact pathology that leads to the aggregation of the  $\beta$  protein is unknown. It has been indicated that various inflammatory pathways and multiple inflammatory mediators play an important role in the progression of Alzheimer's disease and therefore is a potential target for its treatment. Currently, there is no curative therapy for Alzheimer's disease, and all treatments are symptomatic. There are mainly 2 approaches that are used in the current therapy of Alzheimer's disease, one is the augmentation of cholinergic transmission[12]. This treatment mainly makes use of reversible AChE (Acetylcholine Esterase) inhibitors like Donepezil, Rivastigmine, and Galantamine. When these drugs are administered in early cases of Alzheimer's disease, they show modest effect in reducing the cognitive impairment. This effect is however short-lived due to the down regulation of cholinergic receptors in the brain upon long term therapy[13]. Generally speaking anticholinergic drugs only delay the onset of the disease by about half a year to one full year at the most, before the clinical progression of the disease begins again. The other approach is relatively new; it involves the use of an NMDA- receptor antagonist called

Memantine[14]. It is usually administered along with anticholinergic drugs, usually administered in the later stages of Alzheimers, as it has little to no effect in the early stages to treat dementia. Memantine is seen to delay the erosion of the mental status of the patients. Other than these 2 approaches, the other treatments used in Alzheimer's disease are usually CNS drugs used to treat paranoia, depression and anxiety[15].

### **Ashwagandha: A Herbal Remedy**

Ashwagandha is the common name for *Withania somnifera*, an evergreen shrub that belongs to the family Solanaceae. It is also called Indian Ginseng and Poison Gooseberry[16]. It grows largely in the North-Western areas of India. Ashwagandha has long been recognized as a medicinal plant in India. Its medicinal properties are well documented in the traditional systems of medicine like Ayurveda, Siddha and Unani-Tibb. It has long been used as a tonic, which is prepared using the powder of the dried roots of the plant. The plant is known to contain several classes of phytoconstituents, such as alkaloids, glycosides and saponins among others[17]. The various phytoconstituents of Ashwagandha has been identified to have many biological activities, of which the anti-inflammatory, antineoplastic, neuroprotective and hepatoprotective properties are of special interest[18-19].

### **Neuroprotective Effect**

Since the exact aetiology of Alzheimer's disease is not known, the general neuroprotective effects produced by the constituents of Ashwagandha bear some importance. Multiple aqueous and alcoholic extracts of the plant were seen to protect nerves from oxidative stress by limiting the formation of free radical species and also minimize the DNA damage[20]. This activity of the plant is mainly attributed to the Withanolides, a class of steroidal lactones[21]. They have been known to promote the reconstruction of neuronal networks, both in-vivo and in-vitro simulations, particularly they are known to decrease the time required for axonal regeneration and synaptic reconstruction[22]. They are also shown to improve object location memory in rats, indicating cognitive improvement. The aqueous extract was also seen to increase neurotransmitter levels, and lower oxidative stress in various animal models[23].




Figure 1: Structures of some phytoconstituents of *Withania somnifera*

### Anti-Alzheimer's Effect

The constituents of *W. somnifera*, along with their general neuroprotective effects, also show activity as potential drugs in the treatment of Alzheimer's disease [24]. It is important to note that the anti-Alzheimer's property of *W. somnifera* cannot be attributed to a single constituent alone. Most of the properties, occur as a result of synergistic action of multiple constituents working through various different mechanisms, that produce the final desirable effect. The aqueous extract of the root, showed improved cognitive and psychomotor abilities in healthy individuals[25]. It was also seen to improve the clearance of  $A\beta$  (Amyloid- $\beta$ ) by the activation of a lipoprotein like protein in the liver. In-silico studies have also shown that 2 constituents, Withanamide A and C bind to  $A\beta$ [26-27], which is indicative of fibril formation inhibition in the neurons and therefore in the long

term, reduce the  $A\beta$  toxicity in the cells. Withanolides are also known to activate P-glycoprotein, thereby increasing the efflux of the amyloid protein[28]. There is also potential disease modifying properties in constituents like Withanosides, which are known to possess neuro-regenerative properties, by promoting regeneration of axons and dendrites. Along with these activities, the Withanolides have some anticholinesterase activity which also helps in improving the condition of dementia in Alzheimer's patients[29]. Since neuroinflammation also plays a role in the progression of the disease, the antiinflammatory properties of the constituents become useful in this regard. Withaferin-A is known to inhibit the migration of cytokines like  $TNF-\alpha$  and Interleukin- $1\beta$  (IL- $1\beta$ ), and therefore can help in the reduction of long-term  $A\beta$  toxicity in the cells[30-31].

## CONCLUSION

The phytoconstituents of *Withania somnifera* have proven to have very beneficial effects in slowing the progression of Alzheimer's disease and in some cases, has also shown very promising activity in reversing the physiological damage caused by Alzheimer's disease through its neuro-regenerative properties, which helps in axonal and synaptic reconstruction. The lack of drugs to satisfactorily treat Alzheimer's disease makes Ashwagandha an ideal starting point to identify a new therapeutic compound.

## ACKNOWLEDGEMENT

The authors are grateful to the authorities of NITTE (Deemed to be University) for providing the facilities.

## Acknowledgements

The authors are thankful to Nitte (Deemed to be University) for providing the necessary facilities to carry out this research.

## CONFLICT OF INTEREST:

No conflict of interest.

## REFERENCES

[1]. Berchtold NC. Cotman CW. Evolution in the conceptualization of dementia and

- Alzheimer's disease: Greco-Roman period to the 1960s. *Neurobiol Aging*. 1998; 19(3): 173–89. doi: 10.1016/s0197-4580(98)00052-9
- [2]. Burns A. Iliffe S. Alzheimer's disease. *BMJ*. 2009; 338. doi: <https://doi.org/10.1136/bmj.b158>
- [3]. Giacobini E. Gold G. Alzheimer disease therapy-moving from amyloid- $\beta$  to tau. *Nat Rev Neurol*. 2013; 9(12):677–86. doi: <https://doi.org/10.1136/bmj.b158>
- [4]. DeTure MA. Dickson DW. The neuropathological diagnosis of Alzheimer's disease. *Molecular Neurodegeneration*. 2019; 14:32. DOI:10.1186/13024-019-0333-5
- [5]. Turner PR. O'Connor K. Tate WP. Abraham WC. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. *Prog Neurobiol*. 2003; 70(1):1–32. doi: 10.1016/s0301-0082(03)00089-3
- [6]. Mendez MF. The accurate diagnosis of early-onset dementia. *Int J Psychiatry Med*. 2006; 36(4):401–12. doi: 10.2190/Q6J4-R143-P630-KW41
- [7]. Atri A. The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management. *Med Clin North Am*. 2019; 103(2):263–93. doi: 10.1016/j.mcna.2018.10.009
- [8]. Mendez MF. Early-onset Alzheimer's disease: nonamnestic subtypes and type 2 AD. *Archives of Medical Research*. 2012; 43(8):677–85. doi: 10.1016/j.arcmed.2012.11.009
- [9]. Borchelt DR. Thinakaran G. Eckman CB. Lee MK. Davenport F. Ratovitsky T. Prada CMetal. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. *Neuron*. 1996; 17(5):1005–13. doi: 10.1016/s0896-6273(00)80230-5
- [10]. Xu H. Finkelstein DI. Adlard PA. Interactions of metals and Apolipoprotein E in Alzheimer's disease. *Front Aging Neurosci*. 2014; 6:121. doi: 10.3389/fnagi.2014.00121
- [11]. Mahley RW. Weisgraber KH. Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. *Proc Natl Acad Sci U S A*. 2006; 103(15):5644–51. doi: 10.1073/pnas.0600549103
- [12]. Selkoe DJ. The therapeutics of Alzheimer's disease: where we stand and where we are heading. *Ann Neurol*. 2013; 74:328–36. doi: 10.1002/ana.24001.
- [13]. Gordon PH. Amyotrophic lateral sclerosis: an update for 2013 clinical features, <http://xisdxjxsu.asia> **VOLUME 17 ISSUE 10 @2021** **222-230**

- pathophysiology, management and therapeutic trials. *Aging Dis.* 2013; 4(5):295–310. doi: 10.14336/AD.2013.0400295
- [14]. Roberson ED. Mucke L. 100 years and counting: prospects for defeating Alzheimer's disease. *Science.* 2006; 314(5800):781–84. doi: 10.1126/science.1132813
- [15]. Schneider LS. Dgerman KS. Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebocontrolled trials. *JAMA.* 2005; 294(15):1934–43. doi: 10.1001/jama.294.15.1934
- [16]. Vaidya AD. The status and scope of Indian medicinal plants acting on central nervous system. *Indian J Pharmacol.* 1997; 29(5):340–3.
- [17]. Mishra LC. Singh BB. Dagenais S. Scientific basis for the therapeutic use of *Withania somnifera* (ashwagandha): A Review. *Altern Med Rev.* 2000; 5(4):334-46.
- [18]. Kumar G. Patnaik R. Exploring neuroprotective potential of *Withania somnifera* phytochemicals by inhibition of GluN2B-containing NMDA receptors: An in silico study. *Med Hypotheses.* 2016; 92:35–43. doi: 10.1016/j.mehy.2016.04.034
- [19]. Dar N.J. Hamid A. Ahmad M. Pharmacologic overview of *Withania somnifera*, the Indian Ginseng. *Cell Mol. Life Sci.* 2015; 72:4445-60. doi: 10.1007/s00018-015-2012-1
- [20]. Banu MR. Ibrahim M. Prabu K. Rajasankar S. Neuroprotective efficacy of withaferin a on aging mediated oxidative stress in striatum and Substantia nigra of wistar albino rat. *Drug Invention Today.* 2019; 12(3), 425-31.
- [21]. Ahmed ME. Javed H. Khan MM. Vaibhav K. Ahmad A. Khan A. Tabassum R et al. Attenuation of oxidative damage-associated cognitive decline by *Withania somnifera* in rat model of streptozotocin-induced cognitive impairment. *Protoplasma.* 2013; 250(5):1067-78. doi: 10.1007/s00709-013-0482-2
- [22]. Kuboyama T. Tohda C. Komatsu K. Neuritic regeneration and synaptic reconstruction induced by withanolide A. *Br J Pharmacol.* 2005; 144:961-71. doi: 10.1038/sj.bjp.0706122
- [23]. Russo A. Izzo AA. Cardile V. Borrelli F. Vanella A. Indian medicinal plants as antiradicals and DNA cleavage protectors. *Phytomedicine.* 2001; 8(2):125-32. doi: 10.1078/0944-7113-00021
- [24]. Bhatnagar M. Sharma D. Salvi M. Neuroprotective effects of *Withania somnifera*

- dunal: A possible mechanism. *Neurochem Res.* 2009; 34(11):1975–83. doi: 10.1007/s11064-009-9987-7
- [25]. Kumar S. Seal CJ. Howes MJ. Kite GC. Okello EJ. In vitro protective effects of *Withania somnifera* (L.) dunal root extract against hydrogen peroxide and -amyloid(1-42)-induced cytotoxicity in differentiated PC12 cells. *Phytother Res.* 2010; 24(10):1567–74. <https://doi.org/10.1002/ptr.3261>
- [26]. Jayaprakasam B. Padmanabhan K. Nair MG. Withanamides in *Withania somnifera* fruit protect PC-12 cells from beta-amyloid responsible for Alzheimer's disease. *Phytother Res.* 2010; 24(6):859-63. doi: 10.1002/ptr.3033
- [27]. Kumar S. Harris RJ. Seal CJ. Okello EJ. An aqueous extract of *Withania somnifera* root inhibits amyloid beta fibril formation in vitro. *Phytother Res.* 2012; 26(1):113-17. doi: 10.1002/ptr.3512
- [28]. Dhuley JN. Effect of ashwagandha on lipid peroxidation in stress-induced animals. *J Ethnopharmacol.* 1998; 60(2):173-78. doi: 10.1016/s0378-8741(97)00151-7
- [29]. Schliebs R. Liebmann A. Bhattacharya SK. Kumar A. Ghosal S. Bigl V. Systemic administration of defined extracts from *Withania somnifera* (Indian Ginseng) and Shilajit differentially affects cholinergic but not glutamatergic and GABAergic markers in rat brain. *Neurochem Int.* 1997; 30(2):181-90. doi: 10.1016/s0197-0186(96)00025-3
- [30]. Dubey S. Yoon H. Cohen MS. Nagarkatti P. Nagarkatti M. Karan D. Withaferin A associated differential regulation of inflammatory cytokines. *Front Immunol.* 2018; 9:195. doi: 10.3389/fimmu.2018.00195
- [31]. Gupta A. Singh S. Evaluation of anti-inflammatory effect of *Withania somnifera* root on collagen-induced arthritis in rats. *Pharm. Biol.* 2014; 52(3):308-20. doi: 10.3109/13880209.2013.835325



Authors:

First Author- Abhishek Kumar, Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS) Department of Pharmaceutical Chemistry, Mangalore, India.

Second Author- Pankaj Kumar, Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS) Department of Pharmaceutical Chemistry, Mangalore, India.

Third author- Prashant Nayak, Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS) Department of Pharmaceutics, Mangalore, India.

Fourth author- S. Pramatha, Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS) Department of Pharmaceutical Chemistry, Mangalore, India.

Fifth author- Rupal Ria Dsouza, Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS) Department of Pharmaceutical Chemistry, Mangalore, India.

Sixth author- Sameeksha Suvarna, Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS) Department of Pharmaceutical Chemistry, Mangalore, India.

Seventh author- Sanil Rohan Kumar, Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS) Department of Pharmaceutical Chemistry, Mangalore, India.

Corresponding Author\*

Dr. Pankaj Kumar,  
Assistant Professor  
Department of Pharmaceutical Chemistry  
NGSM Institute of Pharmaceutical Sciences,  
Nitte (Deemed to be University),  
Paneer, Deralakatte, Mangaluru-575018,  
Karnataka, India.  
e-mail: pankajpgr@nitte.edu.in  
Contact no. +918746063684